GlassScriptPhysician profile
Natasha C Struewing
NPI 1346556164
$4,582.61
in general payments reported to CMS, 2019-2025
37 companies · $673 in 2025
The $673 reported for 2025 was more than what 91% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,112 · 2022: $1,184 · 2023: $822 · 2024: $791 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,652.29 | 2021-2025 | |
| Novo Nordisk INC | $336.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.47 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $205.52 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $189.41 | 2021-2025 | Prolia, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $177.10 | 2021-2023 | |
| Glaxosmithkline, LLC. | $158.83 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $147.83 | 2021-2023 | |
| Pfizer INC. | $143.85 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.20 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $124.32 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.15 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $92.04 | 2021-2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $79.35 | 2021 | |
| Astellas Pharma US INC | $79.05 | 2024-2025 | Veozah |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Struewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.